SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Data Sheet (Cat.No.T73350)

TargetMol

BAY-3827

Chemical Properties



CAS No. : 2377576-35-5

Formula: C27H25FN6O

Molecular Weight: 468.53

Appearance: no data available

Storage: keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	BAY-3827 is a potent and selective AMPK inhibitor with potential antitumor activity, showing antiproliferative activity in an androgen-dependent prostate cancer model. BAY-3827 inhibits the phosphorylation of acetyl CoA carboxylase 1.
Targets(IC50)	Acyltransferase,AMPK
In vitro	BAY-3827, in the concentration range of 0-200 μM, inhibits AMPK kinase activity with IC50 values of 1.4 nM at low ATP concentration (10 μM) and 15 nM at high ATP concentration (2 mM)[1].In the concentration range of 0-200 μM, BAY-3827 inhibits Aurora A, Flt3, c-Met, and Rsk4 with IC50 values of 1324, 124, 788, and 36 nM, respectively, at 10 μM ATP concentration[1].After overnight treatment, BAY-3827 strongly reduces ACC1 Ser79 phosphorylation in LNCaP and VCaP cells, with a lesser extent in IMR-32 and especially in Colo320 cells[1].At concentrations of 0-10 nM over 6 days, BAY-3827 exhibits strong inhibitory effects on LNCaP and VCaP cells[1].At concentrations of 1 and 5 μM over 24 and 48 hours, BAY-3827 represses LIPE gene expression, reduces serine/threonine kinase AKT3, and blocks the expression of several genes from the mitochondrial carnitine palmitoyltransferase (CPT) family, which is involved in acyl carnitine formation in VCaP cells[1]. At a concentration of 5 μM over 2-4 days, BAY-3827 significantly increases the formation of lipid droplets compared to androgen treatment only[1].

Solubility Information

Solubility	DMSO: 20 mg/mL (42.69 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1343 mL	10.6717 mL	21.3434 mL
5 mM	0.4269 mL	2.1343 mL	4.2687 mL
10 mM	0.2134 mL	1.0672 mL	2.1343 mL
50 mM	0.0427 mL	0.2134 mL	0.4269 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Lemos C, et al. The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models. Cell Oncol (Dordr). 2021 Jun;44(3):581-594.